



## Access to Experts



**Mark A. Wingertzahn, Ph.D.** , Head of Alliance Management and Science Director R&D , Nycomed US

Mark A. Wingertzahn, Ph.D. is currently the Head of Alliance Management and Senior Director R&D for Nycomed. In his current position, Dr. Wingertzahn leads the Nycomed Alliance Center whose mission is to “shepherd partnerships over the alliance lifecycle to achieve mutually successful relationships by operationalizing, executing and optimizing delivery of partner agreements in a coordinated effort, thereby maximizing project/product value.”

Dr. Wingertzahn has nearly 15 years of commercial and R&D experience within the pharmaceutical industry. His experience within the pharmaceutical industry has been focused on marketing, development and maximizing alliances of drugs to treat respiratory, cardiovascular and endocrinologic disorders.

Prior to entering the pharmaceutical industry, Dr. Wingertzahn held a faculty position at the New York University School of Medicine in the Department of Perinatology. During his 5-year tenure at N.Y.U. his research focused on modalities to enhance nutrient and small molecule uptake from the gastrointestinal tract in neonatal infants.

Based largely upon his research within academia and the pharmaceutical industry, Dr. Wingertzahn has authored over 50 peer-reviewed publications and book chapters.

Contact [Carol Courter](mailto:courter@conferenceboard.org), Manager, Corporate Communications, +1 212 339 0232, [courter@conferenceboard.org](mailto:courter@conferenceboard.org)

The Conference Board is a global, independent business membership and research association working in the public interest. Our mission is unique: to provide the world's leading organizations with the practical knowledge they need to improve their performance and better serve society. The Conference Board is a non-advocacy, not-for-profit entity holding 501 (c)(3) tax-exempt status in the United States of America.

